Tuesday, December 7th, 2021

Pfizer claims that their COVID-19 tablet reduces hospitalizations and deaths by 89 percent

Pfizer has claimed that their experimental antiviral pill for COVID-19 reduces the risk of hospitalization and mortality by over 90%, as drugmakers race to develop an easy-to-use treatment against the coronavirus.

Pharmaceutical companies are having a race to develop simple anti-coronavirus medications that are highly effective.

Pfizer antiviral pill

On Friday, the pharmaceutical company presented preliminary findings from a trial of 775 adults. People receiving the company’s medicine in combination with another antiviral had an 89 percent lower cumulative rate of hospitalization or death after a month when compared to patients taking a dummy pill.

Fewer than 1% of individuals taking the medicine required hospitalization, and no one died. In the comparison group, 7% were hospitalized, and seven people died.

“We were hoping for something remarkable, but it’s rare to see fantastic treatments come through with about 90% efficacy and 100% protection against death,” Pfizer’s chief scientific officer, Mikael Dolsten, told The Associated Press news agency.

Participants in the study were unvaccinated, had mild-to-moderate COVID-19, and were classified at high risk for hospitalization due to health issues such as obesity, diabetes, or heart disease. Treatment began three to five days after the onset of symptoms and lasted five days.

Within three days of symptom onset, 0.8 percent of those receiving Pfizer’s medication were hospitalized, and none died by 28 days of therapy. In comparison, placebo patients were hospitalized at a rate of 7%. In addition, seven people died in the placebo group.

Rates were comparable for patients treated within five days of onset of symptoms – 1% of the treatment group was hospitalized, compared to 6.7 percent of the placebo group, which included 10 deaths. Pfizer Chief Executive Albert Bourla remarked in an interview with US channel CNBC that this works out to be 85 percent effective.

Pfizer provided scant specifics on side effects but stated that they were light and that the incidence of difficulties was similar between groups, at around 20%.

Connect with Us

Leave a Reply

Your email address will not be published. Required fields are marked *